Top 30 Anti-tumor Drugs in 2023 (In billion dollars)
Top 30 Anti-tumor Drugs in 2023 (In billion dollars)
| No. | Drug name | Company | Main indications | Sales | Growth rate |
| 1 |
Keytruda (pembrolizumab) |
MSD | Melanoma, NSCLC, Bladder cancer, HNC | 25.01 | 19.5% |
| 2 |
Opdivo (nivolumab) |
BMS/ONO | Melanoma, NSCLC, HNC | 10.04 | 9.0% |
| 3 |
Darzalex (daratumumab) |
Johnson & Johnson | Multiple myeloma, AL amyloidosis | 9.74 | 22.2% |
| 4 |
Imbruvica (ibrutinib) |
Abbvie/Joshnson | CLL/SLL, MCL, GVHD | 6.86 | -17.9% |
| 5 |
Revlimid (lenalidomide) |
BMS | MM, MDS, MCL, FL | 6.10 | -39.0% |
| 6 |
Tagrisso (osimertinib) |
Astrazeneca | T790M NSCLC | 5.80 | 7.0% |
| 7 |
Xtandi (enzalutamide) |
Astellas | Prostate cancer | 5.07 | 4.3% |
| 8 |
Ibrance (palbociclib) |
Pfizer | Breast cancer | 4.75 | -6.0% |
| 9 |
Jakafi (ruxolitinib) |
Incyte/Norvatis | Myelofibrosis, PV | 4.31 | 8.7% |
| 10 |
Imfinzi (durvalumab) |
Astrazeneca | Urothelial carcinoma,NSCLC, SCLC etc | 4.24 | 52.0% |
| 11 |
Perjeta (Pertuzumab) |
Roche | HER2+ breast cancer | 4.21 | 1.0% |
| 12 |
Tecentriq (atezolizumab) |
Roche | Urothelial carcinoma,NSCLC, TNBC | 4.21 | 9.0% |
| 13 |
Verzenio (abemaciclib） |
Eli Lilly | Breast cancer | 3.86 | 56.0% |
| 14 |
Pomalyst (pomalidomide) |
BMS | Multiple myeloma | 3.44 | -2.0% |
| 15 |
Lynparza (olaparib) |
Astrazeneca/MSD | Ovarian cancer, Breast cancer, Pancreatic cancer, Prostate cancer | 2.81 | 7.0% |
| 16 |
Enhertu (trastuzumab deruxtecan) |
Daiichi Sankyo/AZ | HER2+ breast cancer, HER2-low brease cancer | 2.57 | 104.8% |
| 17 |
Calquence (acalabrutinib) |
Astrazeneca | Mantle cell lymphoma, CLL/SLL | 2.51 | 22.0% |
| 18 |
Erleada (apalutamide) |
Johnson & Johnson | Prostate cancer | 2.39 | 26.9% |
| 19 |
Venclexta (venetoclax) |
Abbvie | CLL, AML | 2.29 | 13.9% |
| 20 |
Revolade/Promacta (eltrombopag) |
Norvatis | Thrombocytopenia | 2.27 | 10.0% |
| 21 |
Yervoy (ipilimumab) |
BMS | Melanoma, RCC, CRC | 2.24 | 5.0% |
| 22 |
Kadcyla (trastuzumab Emtansine) |
Roche | HER2+ breast cancer | 2.19 | 4.0% |
| 23 |
Xgeva (denosumab) |
Amgen | Solid tumor bone metastasis | 2.11 | 5.0% |
| 24 |
Kisqali (Ribociclib) |
Norvatis | HR+ breast cancer | 2.08 | 75.0% |
| 25 |
Lenvima (lenvatinib) |
Eisai/MSD | DTC, HCC, Endometrial carcinoma | 2.01 | 8.4% |
| 26 |
Sprycel (dasatinib) |
BMS | ALL, CML | 1.93 | -11.0% |
| 27 |
Tafinlar+Mekinist (dabrafenib+trametinib） |
Norvatis | Melanoma, NSCLC, ATC | 1.92 | 11.0% |
| 28 |
Tasigna (nilotinib) |
Norvatis | CML | 1.85 | -3.0% |
| 29 |
Herceptin (trastuzumab) |
Roche | HER2+ breast cancer | 1.82 | -16.0% |
| 30 |
Avastin (bevacizumab) |
Roche | CRC, Breast cancer, Lung cancer, Ovarian cancer etc | 1.76 | -19.0% |
